Largactil injection is a phenothiazine neuroleptic. It is indicated in the following conditions: - Schizophrenia and other psychoses (especially paranoid) mania and hypomania. - Anxiety, psychomotor agitation, excitement, violent or dangerously impulsive behaviour. Largactil is used as an adjunct in the short-term treatment of these conditions. - Intractable hiccup. - Nausea and vomiting of terminal illness (where other drugs have failed or are not available). - Childhood schizophrenia and autism.
The FDA has given approval for the Abbreviated New Drug Application (ANDA) for acetylcysteine injection, from APP Pharma, indicated to...
Basilea Pharmaceutica Ltd, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced that the FDA approved Zevtera (ceftobiprole medocaril sodium for injection), for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis, and adult patients with acute bacterial skin and skin structure infections (ABSSSI) and for adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP)
Mylan N.V. announced that the FDA has approved Mylan's Abbreviated New Drug Applications (ANDAs) for Glatiramer Acetate Injection 40 mg/mL...
Genentech has announced that the FDA has approved Lucentis (ranibizumab injection) 0.5 mg for the treatment of patients with myopic...
Eton Pharmaceuticals announced that the FDA has accepted for review the Company’s New Drug Application (NDA) response for dehydrated alcohol injection for the proposed indication of methanol poisoning
The FDA has approved Eli Lilly's Humulin R U-500 KwikPen (insulin human injection) 500 units/mL, a pre-filled device containing Humulin...